Find related topics. | Discover entities. | See connections. | Build a topical map.
Building topical map: Starting…
SGLT2 inhibitor: Applications, Research, Members & Measurement
SGLT2 inhibitors (also called gliflozins or flozins) are a class of medications that inhibit sodium-glucose transport proteins in the nephron (the functional units of the kidney), unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and…
Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.
More settings
SGLT2 inhibitor topic overview
The analysis highlights Applications, Research, Members and Measurement as prominent areas in the source structure around SGLT2 inhibitor.
Related topics
129
Source areas
9
Connected nodes
138
Extracted relationships
113
Concept neighborhoods
36
Bridge connections
138
What this topic covers Research coverage
Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.
Members · 21 topics
Pharmacology · 20 topics
Adverse effects · 16 topics
Medical uses · 15 topics
Research · 15 topics
Mechanism of action · 14 topics
Overview · 12 topics
Structure-activity relationship · 10 topics
Interactions · 6 topics
Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.
Key facts & relationships
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Explore all related topics Closing gaps
A structured outline of related entities, concepts and subtopics. Open any item to build a new map centered on it.
Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
How SGLT2 inhibitor connects Entity context
Entity context groups extracted connections by relationship type. Counts show recurrence in the analyzed source; the examples are research signals, not claims about importance.
The extracted context around SGLT2 inhibitor shows recurring relationship patterns in the source. For example, SGLT2 inhibitor → Apleway, Approved, Astellas Pharma Inc, August, Bexagliflozin, Boehringer Ingelheim, Boehringer Ingelheim Animal Health, Brenzavvy, Canagliflozin, China, Daewoong Pharmaceutical, Dapagliflozin, Deberza, December, Drug Administration, Ecuador, Empagliflozin, Enavogliflozin, Ertugliflozin, EU Another extracted example is SGLT2 inhibitor → Archived, December, Drug Administration, FDA, FDA Drug Safety Communication, Food, Interim, Invokamet, Invokamet XR, Invokana, January, May, November, October, September, SGLT2, Warning. Use these groups to spot repeated connection types before inspecting the individual relationships.
Relationships are represented as Subject → Predicate → Object triples. Confidence describes extraction strength, not the real-world importance of a relationship; lower-confidence rows may be contextual rather than explicit.
TTTA extracted 113 structured relationships around SGLT2 inhibitor. Examples in this analysis include sulfonylureas → instance of → Using gliflozins in combination therapy with metformin can lower the risk of hypoglycemia compared to other type 2 diabetes treatments and natriuresis → instance of → Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions. The table shows each extracted connection, where it came from and its confidence.
Subject
Predicate
Object
Confidence
Src
sulfonylureas
instance of
Using gliflozins in combination therapy with metformin can lower the risk of hypoglycemia compared to other type 2 diabetes treatments
0.80
text
insulin.Increased risk of lower limb amputation is associated with canagliflozin
instance of
Using gliflozins in combination therapy with metformin can lower the risk of hypoglycemia compared to other type 2 diabetes treatments
0.80
text
but further data is needed to confirm this risk associated with different gliflozins
instance of
Using gliflozins in combination therapy with metformin can lower the risk of hypoglycemia compared to other type 2 diabetes treatments
0.80
text
natriuresis
instance of
Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions
0.80
text
hemoconcentration
instance of
Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions
0.80
text
deactivation of renin
instance of
Pleiotropic effects of this class have been attributed to a variety of its pharmacodynamic actions
0.80
text
SGLT2 inhibitor
has effect
Genital
0.60
section
SGLT2 inhibitor
has effect
In
0.60
section
SGLT2 inhibitor
has effect
In May
0.60
section
SGLT2 inhibitor
has effect
FDA
0.60
section
SGLT2 inhibitor
has effect
DKA
0.60
section
SGLT2 inhibitor
has effect
By
0.60
section
No triples extracted yet.
Related concept clusters Concept neighborhoods
Concept neighborhoods group terms that sit near one another in the extracted graph. They are useful for discovering adjacent language and context, but proximity does not by itself imply a factual relationship.
The concept neighborhoods around SGLT2 inhibitor bring nearby vocabulary together. In this analysis, examples include Diabetes, Type and Effects. Use the clusters to find adjacent concepts and terminology that may deserve separate research.
SGLT2 inhibitor
Diabetes
Type
Effects
First
Inhibitor
Sglt2
Adverse
Dapagliflozin
Fda
Approved
Cardiovascular
May
sglt2 inhibitor
Diabetes
Type
Effects
First
Inhibitor
Sglt2
Adverse
Dapagliflozin
Fda
Risk
Approved
Cardiovascular
kidney
Function
Blood
Adverse
Cardiovascular
Sglt-2
Patients
Sugar
Sglt2
Type
Fda
Glucose
Diabetes
sglt1 inhibitors
Sglt2
Diabetes
Adverse
Effects
Sglt-2
Type
Also
Medications
Patients
Cardiovascular
Function
Kidney
reabsorption of glucose in the kidney
Blood
Sodium
Function
Lower
Adverse
Therefore
Cardiovascular
Sglt-2
Sugar
Patients
Sglt2
Type
blood sugar
Sugar
Glucose
Lower
Gliflozins
Kidney
Therefore
Class
Body
Medications
Ketone
Medication
Sodium
type 2 diabetes
Diabetes
Type
Cardiovascular
Inhibitors
Sglt2
Drug
Risk
Fda
Medications
Also
Effects
First
blood pressure
Sugar
Glucose
Lower
Gliflozins
Kidney
Class
Body
Therefore
Medications
Sodium
Ketone
Clinical
Connections between topic areas Semantic bridges
Semantic bridges connect parts of the graph that would otherwise be more separate. A bridge is a structural signal in this analysis, not a claim that the two topic areas are equivalent.
For SGLT2 inhibitor, one of the stronger structural bridges in this analysis connects SGLT2 inhibitor with Members. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.
Number of nodes, edges, triples, density and central hubs. Use it to gauge the size and connectivity of the map.
SGLT2 inhibitor
Nodes139
Edges138
Triples113
Avg. degree1.99
Density0.014388
Components1
Source & methodology
TTTA analyzes the structure around SGLT2 inhibitor to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as Applications, Research, Members & Measurement, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.
